MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
(See required screening study ECOG-ACRIN EAY131)
All new treatment assignments to EAY131 (MATCH) Subprotocol Z1I, EAY131-Z1I, are suspended effective immediately, 06/27/18,due to meeting it’s accrual goal.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, email@example.com or 406-969-6067, for the consent & for any questions.